Bayer Doubles Down on American Manufacturing as Pipeline and Balance Sheet Get a Rework
Article excerpt
Bayer is betting that scale in the world's largest pharmaceutical market will eventually pay for itself. The Leverkusen-based group wants to double its US pharma revenue by the end of the decade, and CEO Bill Anderson is staking that ambition on building out domestic capacity rather than leaning on imports. The centerpiece of that strategy landed Friday: a roughly $2.2 billion manufacturing complex in New Albany, Ohio, where Bayer intends to combine active ingredient output with finished-dose production under one roof. The site will span 200 acres. Construction alone is expected to generate about 1,500 building trades jobs, with some 600 permanent, highly skilled positions once the facility is running. Patience will be required. The plant is not slated to come online until 2031, and finished-drug production is penciled in for 2034 at the earliest. That long runway sits at the heart of investor caution toward the stock, since years will pass before the new capacity contributes measurable margin - a stretch during which financial discipline has to hold. The Ohio project is not a standalone gesture. Bayer has invested more than $7 billion in US pharmaceutical research, development and production over the past five years, according to the Deutsche Presse-Agentur. The company's US push is concentrated on cancer, heart disease and kidney conditions, the therapeutic areas where it...
Keep reading with a free account
The rest of this article, and every signal for Bayer, is in your free account.
Extracted from this sentence
On Thursday the group named Dr. Christoph Koenen as Chief Medical Officer of its pharma division, effective October 1.
